Name: 글로벌 시장 동향
SKU: BT3183
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 현장 혼성화(In Situ Hybridization, ISH) 시장은 2022년 97억 40만 달러에 달했으며, 2030년까지 150억 8,746만 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 이 시장은 예측 기간(2023~2030년) 동안 연평균 11.9%의 성장률을 기록할 것으로 예상됩니다.
현장 혼성화(ISH)는 표지된 상보적 DNA, RNA 또는 변형된 핵산 가닥(즉, 프로브)을 사용하여 조직의 일부 또는 단면, 또는 조직 크기가 충분히 작은 경우 전체 조직(예: 식물 종자, 초파리 배아), 세포 및 순환 종양 세포(CTC)에서 특정 DNA 또는 RNA 서열의 위치를 확인하는 기술입니다. 조직 절편에서 단백질의 위치를 확인하는 데 주로 사용되는 면역조직화학은 이와는 다른 방법입니다.
시장 동향
암 발병률 증가
흡연과 잘못된 식습관은 암 발병률 증가의 주요 원인입니다. 이는 ISH 시장의 중요한 성장 요인입니다. 예를 들어, 세계보건기구(WHO)는 2020년 전 세계적으로 암이 사망 원인 1위가 될 것이며, 약 1천만 명, 즉 6명 중 1명꼴로 사망에 이를 것이라고 보고했습니다. 유방암, 폐암, 대장암, 직장암, 전립선암이 가장 흔한 암 유형입니다. 흡연, 높은 체질량 지수, 음주, 과일과 채소 섭취 부족, 운동 부족은 암 관련 사망의 약 3분의 1을 차지합니다.
저소득 및 중저소득 국가에서는 인유두종바이러스(HPV) 및 간염을 포함한 암 유발 감염이 암 사례의 30%를 차지하는 것으로 추정됩니다. 결과적으로, 향후 예측 기간 동안 현장 혼성화(ISH)에 대한 수요가 증가할 것으로 예상됩니다.
숙련된 인력 부족은 시장 성장을 저해할 것입니다.
ISH 기반 검사를 수행하려면 염색체 또는 유전자의 분자적 특성에 대한 지식이 필요합니다. 수동 절차에서 자동화 절차로의 전환에 대한 저항은 업계 성장의 또 다른 장벽입니다. 너무 많은 공급업체로 인해 수동 또는 구식 프로세스에서 IT 기반 프로세스로의 전환이 어렵거나 불가능에 가깝습니다. 이로 인해, 특히 개발도상국에서는 자격을 갖추고 교육을 잘 받았으며 기술적으로 숙련된 실험실 인력이 부족하여 ISH 기반 진단의 광범위한 사용이 제한됩니다.
세그먼트 분석
글로벌 현장 혼성화(FISH) 시장은 제품, 기술, 응용 분야, 최종 사용자 및 지역별로 세분화됩니다.
기술 기준으로 FISH가 가장 큰 비중을 차지할 것으로 예상됩니다.
전 세계적으로 정형외과 수술 건수가 증가함에 따라 FISH 부문이 현장 혼성화 시장에서 가장 큰 비중을 차지할 것으로 예상됩니다. 예를 들어, 형광 현장 혼성화(FISH) 실험실 절차를 사용하여 사람의 염색체를 유리 슬라이드에 부착하고, 형광 염색된 정제된 DNA로 만들어진 프로브에 염색체를 노출시킵니다. FISH(형광 in situ hybridization)는 암, 염색체 이상, 유전자 지도 작성 및 유전 질환 진단에 사용됩니다. 유전 질환, 만성 질환의 증가와 효과적인 진단 방법에 대한 수요 증가는 FISH 시장 확장의 주요 요인입니다. 또한 다양한 시장 참여자들이 더 많은 제품을 출시함에 따라 FISH 방법에 대한 수요 증가로 시장이 확대됩니다.
예를 들어, Vizgen은 2021년 5월, 새롭게 시작한 제품 출시 프로그램의 일환으로 공개적으로 접근 가능한 데이터 컬렉션을 공개했습니다. 483개 유전자의 전사체 정확한 위치는 Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map으로 알려진 오픈 소스 공간 유전체학 데이터 세트에서 확인할 수 있습니다. 따라서 위에서 언급한 요인들이 FISH 시장이 시장을 주도하는 데 기여하고 있습니다.
지리적 침투
감염성 질환 및 유전적 이상 발생률 증가가 지역 성장을 견인
북미 지역의 FISH 시장은 주요 업체들의 제품 출시 증가로 인해 예측 기간 동안 성장할 것으로 예상됩니다. 예를 들어, 북미 지역은 감염성 질환, 유전적 이상, 암 발병률이 높기 때문에 현장 혼성화(in situ hybridization) 시장에서 상당한 시장 점유율을 차지할 것으로 예상됩니다. 또한 연구 개발 노력 증가, 주요 업계 경쟁업체의 존재, 그리고 정기적인 신제품 출시로 인해 시장 규모가 더욱 확대될 것으로 전망됩니다. 예를 들어, 미국 암 협회(American Cancer Society)에 따르면 2022년 신규 암 발병 및 사망자 수는 약 190만 건으로 추산되며, 609,360명이 암으로 사망할 것으로 예상됩니다. 2022년 특별 섹션에서는 미국 원주민 및 알래스카 원주민(AIAN) 인구의 암 위험 요인 및 검진 현황을 살펴봅니다.
경쟁 환경
시장의 주요 글로벌 업체로는 Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat GmbH, Zytovision 등이 있습니다.

COVID-19 영향 분석
제품별
• 소모품
• 기기
• 소프트웨어
기술별
• FISH
o DNA FISH
o RNA FISH
o PNA FISH
• CISH
응용 분야별
• 암 진단
• 세포학
• 감염병 진단
• 신경과학
• 면역학
최종 사용자별
• 병원 및 진단 연구소
• 학술 및 연구 기관
• 제약 및 생명공학 회사
• 연구 위탁 기관
지역별
• 북미
o 미국
o 캐나다
o 멕시코
• 유럽
o 독일
o 영국
o 프랑스
o 이탈리아
o 러시아
o 기타 유럽
• 남미
o 브라질
o 아르헨티나
o 기타 남미
• 아시아 태평양
o 중국
o 인도
o 일본
o 호주
o 기타 아시아 태평양
• 중동 및 아프리카
주요 동향
• 2021년 4월 6일, Applied Spectral Imaging(ASI)과 전략적 사업 제휴 체결 KromaTiD, Inc.와의 파트너십이 발표되었습니다. 이 파트너십을 통해 ASI는 KromaTiD가 개발한 Pinpoint FISH(PPF) 프로브 및 테스트 서비스를 전 세계적으로 독점적으로 제공할 수 있는 권리를 갖게 됩니다.
• 2020년 3월 10일, Creative Bioarray는 2019년 신종 코로나바이러스를 식별하는 개선된 FISH 프로브를 출시했습니다. 감염된 세포 내 바이러스 입자는 현장 혼성화(ISH)를 사용하여 식별할 수 있으며, 이는 감염된 세포 유형 및 영역의 정확한 분자 식별 및 시각화를 제공합니다.

• 2020년 5월 26일, Leica Biosystems와 Bio-Techne는 BOND-III 플랫폼 자동화를 위한 CE-IVD 인증 RNAscope In Situ Hybridization Detection Kit를 유럽에서 출시했습니다. Leica의 플랫폼과 Bio-RNAscope Techne는 병리학자들에게 진단 실험실 운영에 도움이 되는 최고의 애플리케이션을 제공합니다.
보고서를 구매해야 하는 이유

• 제품, 기술, 응용 분야, 최종 사용자 및 지역별 글로벌 현장 혼성화(In Situ Hybridization) 시장 세분화를 시각화하고 주요 상업 자산 및 주요 업체를 파악합니다.

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 발굴합니다.

• 모든 세그먼트를 포함한 현장 혼성화 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 업체들의 핵심 제품을 포함한 제품 맵핑 자료를 엑셀 파일로 제공합니다.

글로벌 현장 혼성화 시장 보고서는 약 61개의 표, 58개의 그림, 195페이지 분량입니다.
주요 대상 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global In Situ Hybridization market reached US$ 9700.40 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 15087.46 million by 2030. The market is growing at a CAGR of 11.9% during the forecast period (2023-2030).
In situ hybridization (ISH) uses a labeled complementary DNA, RNA, or modified nucleic acid strand (i.e., probe) to localize a particular DNA or RNA sequence in a portion or section of tissue, or if the tissue is small enough, in the entire tissue (e.g., plant seeds, Drosophila embryos), in cells, and in circulating tumor cells (CTCs). Immunohistochemistry, which often localizes proteins in tissue slices, is different from this.
Market Dynamics
The Increasing incidence of Cancer cases
Smoking and poor eating habits are to responsible for the increase in cancer occurrences. That is a significant growth factor for the ISH market. For instance, the WHO reports that cancer will be the top cause of mortality globally in 2020, accounting for around 10 million deaths, or roughly one in every six. Breast, lung, colon, rectum, and prostate cancers are the most prevalent types of cancer. The use of tobacco, having a high body mass index, drinking alcohol, eating few fruits and vegetables, and not exercising account for about one-third of cancer-related fatalities.
In low- and lower-middle-income nations, cancer-causing infections including the human papillomavirus (HPV) and hepatitis are thought to be the cause of 30% of cancer cases. And as a result, in-situ hybridization demand is increasing during the anticipated period.
The Lack of trained personnel will hamper the market.
To carry out an ISH-based test, one needs to be aware of the molecular specifics of a chromosome or gene. Resistance to the transition from manual to automated procedures is another barrier to the industry's growth. Too many suppliers, making the transfer from manual or antiquated processes to IT-based ones is challenging, if not impossible. Because of this, the broad use of ISH-based diagnosis is limited, particularly in developing countries, by a lack of qualified, educated, and technically adept laboratory personnel.
Segment Analysis
The global In Situ Hybridization market is segmented based on product, technology, application, end user,and region.
On basis of the technology, FISH isexpected to hold the largest share
The FISH segment is expected to hold the largest share in the In Situ Hybridization market owing to the increasing number oforthopedic surgeries across the globe. For instance, a chromosome from a person is attached to a glass slide using the Fluorescence In Situ Hybridization (FISH) laboratory procedure, which exposes the chromosome to a probe made of purified DNA that has been fluorescently dyed. It is used to diagnose cancer, chromosomal abnormalities, gene mapping, and genetic illnesses. Growing genetic problems, chronic diseases, and rising demand for effective diagnostic methods are factors in the expansion of the FISH segment. And when more products are released by different market players, the market expands as a result of the rising demand for FISH methods.
For instance, in May 2021, as a part of its newly launched Vizgen release program, Vizgen launched its publicly accessible data collection. The precise location of transcripts from 483 genes can be found in the open-source spatial genomics dataset known as the Vizgen multiplexed error resilient fluorescence in situ hybridization mouse brain receptor map. Therefore, the above-mentioned factors help the FISH segment to dominate the market.
Geographical Penetration
Rising higher rates of infectious diseases, genetic abnormalities drives the region
North America’sIn Situ Hybridization market is anticipated to grow in the forecast period owing to increasing product launches by the key players in the region. For instance, because to the region's higher rates of infectious diseases, genetic abnormalities, and cancer, North America is anticipated to hold the majority of the market share for in situ hybridization. The market is also anticipated to increase as a result of increasing research and development efforts, the existence of major industry competitors, and regular product debuts. For instance, estimated numbers of new cancer cases and fatalities in 2022, according of the American Cancer Society (In 2022, there will be an estimated 1.9 million new cancer cases diagnosed and 609,360 cancer deaths in the United States.). The 2022 year special section examines the prevalence of cancer risk factors and screening among American Indian and Alaska Native (AIAN) people.
Competitive Landscape
The major global players in the market include Abbott Laboratories, F. Hoffmann-La Roche Ag, Becton, Dickinson And Company, Agilent Technologies, Inc, Thermo Fisher Scientific, Bio-Rad Laboratories, Inc, Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.
COVID-19 Impact Analysis
By Product
• Consumables
• Instruments
• Software
By Technology
• FISH
o DNA FISH
o RNA FISH
o PNA FISH
• CISH
By Application
• Cancer Diagnostics
• Cytology
• Infectious Disease Diagnostics
• Neuroscience
• Immunology
By End User
• Hospitals & Diagnostic Laboratories
• Academic & Research Institutes
• Pharmaceutical & Biotechnology Companies
• Contract research organizations
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o UK
o France
o Italy
o Russia
o Rest of Europe
• South America
o Brazil
o Argentina
o Rest of South America
• Asia-Pacific
o China
o India
o Japan
o Australia
o Rest of Asia-Pacific
• Middle East and Africa
Key Developments
• In April 6, 2021, A strategic business relationship between Applied Spectral Imaging (ASI) and KromaTiD, Inc. has been announced. Under this partnership, ASI will have the exclusive worldwide rights to offer Pinpoint FISH (PPF) probes and test services developed by KromaTiD.
• In March 10, 2020, an Improved FISH Probe is Introduced by Creative Bioarray to Identify 2019 New Coronavirus. Viral particles in infected cells can be recognized using in site hybridization (ISH), which also offers precise molecular identification and visualization of infected cell types and regions.
• On May 26, 2020, The CE-IVD designated RNAscope In Situ Hybridization Detection Kit for automation on the BOND-III platform has been made available in Europe by Leica Biosystems and Bio-Techne. Leica's platform and Bio-RNAscope Techne will give pathologists access to the top applications to help their diagnostics labs.
Why Purchase the Report?
• To visualize the global In Situ Hybridization- market segmentation based on product, technology, application, end-user, and region, as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of In Situ Hybridization market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global In Situ Hybridization market report would provide approximately 61 tables, 58 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Type
3.2. Snippet by Application
3.3. Snippet by End User
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing incidence of Cancer cases
4.1.1.2. Awareness about companion diagnostics
4.1.1.3. XX
4.1.2. Restraints
4.1.2.1. Lack of trained personnel will hamper the market
4.1.2.2. XX
4.1.3. Opportunity
4.1.3.1. XX
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Forces Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Unmet needs
5.6. Pipe line analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Before COVID-19 Scenario
6.1.2. Present COVID-19 Scenario
6.1.3. PostCOVID-19 or Future Scenario
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Product
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
7.1.2. Market Attractiveness Index, By Type
7.2. Consumables*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Instruments
7.4. Software
8. By Technology
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
8.1.2. Market Attractiveness Index, By Application
8.2. FISH*
8.2.1. DNA FISH
8.2.2. RNA FISH
8.2.3. PNA FISH
8.2.4. Introduction
8.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. CISH
9. By Application
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), ByApplication
9.1.2. Market Attractiveness Index, By Application
9.2. Cancer Diagnostics*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Cytology
9.4. Infectious Disease Diagnostics
9.5. Neuroscience
9.6. Immunology
10. By End User
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
10.1.2. Market Attractiveness Index, By Application
10.2. Hospitals & Diagnostic Laboratories*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Academic & Research Institutes
10.4. Pharmaceutical & Biotechnology Companies
10.5. Contract research organizations
11. By Region
11.1. Introduction
11.1.1. Market Size Analysis andY-o-Y Growth Analysis (%), By Region
11.1.2. Market Attractiveness Index, By Region
11.2. North America
11.2.1. Introduction
11.2.2. Key Region-Specific Dynamics
11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.2.7. Market Size Analysis andY-o-Y Growth Analysis (%), By Country
11.2.7.1. U.S.
11.2.7.2. Canada
11.2.7.3. Mexico
11.3. Europe
11.3.1. Introduction
11.3.2. Key Region-Specific Dynamics
11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.3.7.1. Germany
11.3.7.2. UK
11.3.7.3. France
11.3.7.4. Italy
11.3.7.5. Russia
11.3.7.6. Rest of Europe
11.4. South America
11.4.1. Introduction
11.4.2. Key Region-Specific Dynamics
11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.4.7.1. Brazil
11.4.7.2. Argentina
11.4.7.3. Rest of South America
11.5. Asia-Pacific
11.5.1. Introduction
11.5.2. Key Region-Specific Dynamics
11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
11.5.7.1. China
11.5.7.2. India
11.5.7.3. Japan
11.5.7.4. Australia
11.5.7.5. Rest of Asia-Pacific
11.6. Middle East and Africa
11.6.1. Introduction
11.6.2. Key Region-Specific Dynamics
11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
12. Competitive Landscape
12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis
13. Company Profiles
13.1. Abbott Laboratories*
13.1.1. Company Overview
13.1.2. Product Portfolio and Description
13.1.3. Financial Overview
13.1.4. Key Developments
13.2. F. Hoffmann-La Roche Ag.
13.3. Becton, Dickinson And Company
13.4. Agilent Technologies, Inc.
13.5. Thermo Fisher Scientific
13.6. Bio-Rad Laboratories, Inc.
13.7. Bio-Techne Corporation
13.8. Creative Bioarray
13.9. Biocat Gmbh
13.10. Zytovision.
LIST NOT EXHAUSTIVE
14. Appendix
14.1. About Us and Services
14.2. Contact Us

언급된 주요 기업들

Abbott Laboratories, 4.	Key Developments, F. Hoffmann-La Roche Ag., Becton, Dickinson And Company, Agilent Technologies, Inc., Thermo Fisher Scientific, Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Creative Bioarray, Biocat Gmbh, Zytovision.

표 목록 (Tables)

List of Tables

Table 1 Global In Situ Hybridization Market Value, By Product, 2023, 2027 & 2031 ($ Million)

Table 2 Global In Situ Hybridization Market Value, By Technology, 2023, 2027 & 2031 ($ Million)

Table 3 Global In Situ Hybridization Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 4 Global In Situ Hybridization Market Value, By End user, 2023, 2027 & 2031 ($ Million)

Table 5 Global In Situ Hybridization Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 6 Global In Situ Hybridization Market Value, By Product, 2023, 2027 & 2031 ($ Million)

Table 7 Global In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 8 Global In Situ Hybridization Market Value, By Technology, 2023, 2027 & 2031 ($ Million)

Table 9 Global In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 10 Global In Situ Hybridization Market Value, By Application, 2023, 2027 & 2031 ($ Million)

Table 11 Global In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 12 Global In Situ Hybridization Market Value, By End user, 2023, 2027 & 2031 ($ Million)

Table 13 Global In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 14 Global In Situ Hybridization Market Value, By Region, 2023, 2027 & 2031 ($ Million)

Table 15 Global In Situ Hybridization Market Value, By Region, 2022-2031 ($ Million)

Table 16 North America In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 17 North America In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 18 North America In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 19 North America In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 20 North America In Situ Hybridization Market Value, By Country, 2022-2031 ($ Million)

Table 21 South America In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 22 South America In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 23 South America In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 24 South America In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 25 South America In Situ Hybridization Market Value, By Country, 2022-2031 ($ Million)

Table 26 Europe In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 27 Europe In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 28 Europe In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 29 Europe In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 30 Europe In Situ Hybridization Market Value, By Country, 2022-2031 ($ Million)

Table 31 Asia-Pacific In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 32 Asia-Pacific In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 33 Asia-Pacific In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 34 Asia-Pacific In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 35 Asia-Pacific In Situ Hybridization Market Value, By Country, 2022-2031 ($ Million)

Table 36 Middle East & Africa In Situ Hybridization Market Value, By Product, 2022-2031 ($ Million)

Table 37 Middle East & Africa In Situ Hybridization Market Value, By Technology, 2022-2031 ($ Million)

Table 38 Middle East & Africa In Situ Hybridization Market Value, By Application, 2022-2031 ($ Million)

Table 39 Middle East & Africa In Situ Hybridization Market Value, By End user, 2022-2031 ($ Million)

Table 40 Abbott Laboratories: Overview

Table 41 Abbott Laboratories: Product Portfolio

Table 42 Abbott Laboratories: Key Developments

Table 43 F. Hoffmann-La Roche Ag.: Overview

Table 44 F. Hoffmann-La Roche Ag.: Product Portfolio

Table 45 F. Hoffmann-La Roche Ag.: Key Developments

Table 46 Becton, Dickinson And Company: Overview

Table 47 Becton, Dickinson And Company: Product Portfolio

Table 48 Becton, Dickinson And Company: Key Developments

Table 49 Agilent Technologies, Inc.: Overview

Table 50 Agilent Technologies, Inc.: Product Portfolio

Table 51 Agilent Technologies, Inc.: Key Developments

Table 52 Thermo Fisher Scientific: Overview

Table 53 Thermo Fisher Scientific: Product Portfolio

Table 54 Thermo Fisher Scientific: Key Developments

Table 55 Bio-Rad Laboratories, Inc.: Overview

Table 56 Bio-Rad Laboratories, Inc.: Product Portfolio

Table 57 Bio-Rad Laboratories, Inc.: Key Developments

Table 58 Bio-Techne Corporation: Overview

Table 59 Bio-Techne Corporation: Product Portfolio

Table 60 Bio-Techne Corporation: Key Developments

Table 61 Creative Bioarray: Overview

Table 62 Creative Bioarray: Product Portfolio

Table 63 Creative Bioarray: Key Developments

Table 64 Biocat Gmbh: Overview

Table 65 Biocat Gmbh: Product Portfolio

Table 66 Biocat Gmbh: Key Developments

Table 67 Zytovision: Overview

Table 68 Zytovision: Product Portfolio

Table 69 Zytovision: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 2 Global In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 3 Global In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 4 Global In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 5 Global In Situ Hybridization Market Share, By Region, 2022 & 2031 (%)

Figure 6 Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 7 Global In Situ Hybridization Market Y-o-Y Growth, By Product, 2022-2031 (%)

Figure 8 Consumables: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 9 Instruments: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 10 Software: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 11 Global In Situ Hybridization Market Y-o-Y Growth, By Technology, 2022-2031 (%)

Figure 12 FISH: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 13 CISH: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 14 Global In Situ Hybridization Market Y-o-Y Growth, By Application, 2022-2031 (%)

Figure 15 Cancer Diagnostics: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 16 Cytology: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 17 Infectious Disease Diagnostics: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 18 Neuroscience: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 19 Immunology: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 20 Global In Situ Hybridization Market Y-o-Y Growth, By End user, 2022-2031 (%)

Figure 21 Hospitals & Diagnostic Laboratories: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 22 Academic & Research Institutes: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 23 Pharmaceutical & Biotechnology Companies: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 24 Contract research organizations: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 25 Sub45: Global In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 26 Global In Situ Hybridization Market Y-o-Y Growth, By Region, 2022-2031 (%)

Figure 27 North America In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 28 North America In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 29 North America In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 30 North America In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 31 North America In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 32 North America In Situ Hybridization Market Share, By Country, 2022 & 2031 (%)

Figure 33 South America In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 34 South America In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 35 South America In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 36 South America In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 37 South America In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 38 South America In Situ Hybridization Market Share, By Country, 2022 & 2031 (%)

Figure 39 Europe In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 40 Europe In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 41 Europe In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 42 Europe In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 43 Europe In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 44 Europe In Situ Hybridization Market Share, By Country, 2022 & 2031 (%)

Figure 45 Asia-Pacific In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 46 Asia-Pacific In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 47 Asia-Pacific In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 48 Asia-Pacific In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 49 Asia-Pacific In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 50 Asia-Pacific In Situ Hybridization Market Share, By Country, 2022 & 2031 (%)

Figure 51 Middle East & Africa In Situ Hybridization Market Value, 2022-2031 ($ Million)

Figure 52 Middle East & Africa In Situ Hybridization Market Share, By Product, 2022 & 2031 (%)

Figure 53 Middle East & Africa In Situ Hybridization Market Share, By Technology, 2022 & 2031 (%)

Figure 54 Middle East & Africa In Situ Hybridization Market Share, By Application, 2022 & 2031 (%)

Figure 55 Middle East & Africa In Situ Hybridization Market Share, By End user, 2022 & 2031 (%)

Figure 56 Abbott Laboratories: Financials

Figure 57 F. Hoffmann-La Roche Ag.: Financials

Figure 58 Becton, Dickinson And Company: Financials

Figure 59 Agilent Technologies, Inc.: Financials

Figure 60 Thermo Fisher Scientific: Financials

Figure 61 Bio-Rad Laboratories, Inc.: Financials

Figure 62 Bio-Techne Corporation: Financials

Figure 63 Creative Bioarray: Financials

Figure 64 Biocat Gmbh: Financials

Figure 65 Zytovision: Financials

글로벌 현장 혼성화 시장 – 2023-2030

Global In Situ Hybridization Market - 2023-2030